Call toll-free: 1-833-656-1056

Your patients may be eligible for the

Elfabrio® (pegunigalsidase alfa-iwxj) Copay Programs

Chiesi Total Care℠ offers 2 copay programs for eligible patients*:

Prescription copay: This covers the medication itself. Patients may pay as little as $0 for their Elfabrio prescription

Infusion assistance copay: This covers infusion supplies and administration (including home infusion). Patients may pay as little as $0 for these expenses

To be eligible for these programs:

- Your patient must be enrolled in Chiesi Total Care. (Enrollment and Authorization Form will be mailed to your patient's home)
- Your patient must have commercial insurance and a valid prescription for a US Food and Drug Administration (FDA)-approved indication for Elfabrio
- Your patient must be a resident of the United States or one of its territories

Please refer to the full Terms and Conditions in the pocket for additional eligibility requirements.

*Government-funded plans are not eligible for patient support services that provide financial support through the programs. Patients receiving treatment or residing in MA or RI are not eligible for home infusion services. To receive home infusion support, patients must be referred to home infusion by their prescribing physician.

Patients can learn about the Elfabrio Copay Programs by visiting chiesitotalcare.com or calling toll-free: 1-833-656-1056.

Indication

Elfabrio® (pegunigalsidase alfa-iwxj) is indicated for the treatment of adults with confirmed Fabry disease.

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Elfabrio administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue Elfabrio immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Elfabrio may be considered.

Prior to Elfabrio administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and infusion-associated reactions (IARs), and instruct them to seek medical care immediately if such symptoms occur.

- If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Elfabrio administration and initiate appropriate medical treatment.

Please see Important Safety Information continued on the back and accompanying Full Prescribing Information in pocket.

ELFABRIO®
(pegunigalsidase alfa-iwxj)

One-stop patient support

Lesa, Chiesi Total Care pharmacist

Chiesi Total Care℠ provides nonfinancial assistance to patients with and without prescription drug coverage

Government-funded plans are not eligible for patient support services that provide financial support through the programs. If your patient is receiving treatment or residing in MA or RI, they are not eligible for infusion assistance. Please see the full Terms and Conditions for additional eligibility requirements.

Visit chiesitotalcare.com

PHONE
1-833-656-1056

FAX
1-636-355-3610

HOURS OF OPERATION
Monday to Friday
7:00 AM – 6:00 PM (Central Time)

LOCATION
17877 Chesterfield Airport Road
Chesterfield, MO 63005

Important Safety Information (continued)

- If a mild to moderate hypersensitivity reaction or IAR occurs, consider slowing the infusion rate or temporarily withholding the dose.

In clinical trials, 20 (14%) Elfabrio-treated patients experienced hypersensitivity reactions. Four Elfabrio-treated patients (3%) experienced anaphylaxis reactions that occurred within 5 to 40 minutes of the start of the initial infusion. The signs and symptoms of hypersensitivity reactions and anaphylaxis included headache, nausea, vomiting, throat tightness, facial and oral edema, truncal rash, tachycardia, hypotension, rigors, urticaria, intense pruritus, moderate upper airway obstructions, macroglossia, and mild lip edema.

In clinical trials, 41 (29%) Elfabrio-treated patients experienced one or more infusion-associated reactions, including hypersensitivity, nausea, chills, pruritus, rash, chest pain, dizziness, vomiting, asthenia, pain, sneezing, dyspnea, nasal congestion, throat irritation, abdominal pain, erythema, diarrhea, burning sensation, neuralgia, headache, paresthesia, tremor, agitation, increased body temperature, flushing, bradycardia, myalgia, hypertension, and hypotension.

A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If glomerulonephritis is suspected, discontinue treatment until a diagnostic evaluation can be conducted.

When switching to Elfabrio from a prior enzyme replacement therapy, the risk of hypersensitivity reactions and infusion-associated reactions may be increased in certain patients with pre-existing anti-drug antibodies (ADAs). Consider monitoring IgG and IgE ADAs and clinical or pharmacodynamic response (eg, plasma lyso-Gb3 levels).

The most common adverse reactions (≥15%) were infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis.

Please see accompanying Full Prescribing Information for Elfabrio, including Boxed Warning, and full Terms and Conditions for additional Chiesi Total Care eligibility requirements.

PP-EF-0459 V1.0

ELFABRIO®
(pegunigalsidase alfa-iwxj)